{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T19:27:26Z","timestamp":1789673246494,"version":"4.0.1"},"reference-count":26,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T00:00:00Z","timestamp":1715558400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Explore the efficacy and safety of donor-derived CLL-1 chimeric antigen receptor T-cell therapy (CAR-T) for relapsed\/refractory acute myeloid leukemia (R\/R AML) bridging to allogeneic hematopoietic stem cell transplantation (allo-HSCT) after remission.<\/jats:p><\/jats:sec><jats:sec><jats:title>Case presentation<\/jats:title><jats:p>An adult R\/R AML patient received an infusion of donor-derived CLL-1 CAR-T cells, and the conditioning regimen bridging to allo-HSCT was started immediately after remission on day 11 after CAR-T therapy upon transplantation. Then, routine post-HSCT monitoring of blood counts, bone marrow (BM) morphology, flow cytometry, graft-versus-host disease (GVHD) manifestations, and chimerism status were performed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Result<\/jats:title><jats:p>After CAR-T therapy, cytokine release syndrome was grade 1. On day 11 after CAR-T therapy, the BM morphology reached complete remission (CR), and the conditioning regimen bridging to allo-HSCT started. Leukocyte engraftment, complete donor chimerism, and platelet engraftment were observed on days +18, +23, and +26 post-allo-HSCT, respectively. The BM morphology showed CR and flow cytometry turned negative on day +23. The patient is currently at 4 months post-allo-HSCT with BM morphology CR, negative flow cytometry, complete donor chimerism, and no extramedullary relapse\/GVHD.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Donor-derived CLL-1 CAR-T is an effective and safe therapy for R\/R AML, and immediate bridging to allo-HSCT after remission may better improve the long-term prognosis of R\/R AML.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2024.1389227","type":"journal-article","created":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T04:23:50Z","timestamp":1715574230000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":15,"title":["Case report: Donor-derived CLL-1 chimeric antigen receptor T-cell therapy for relapsed\/refractory acute myeloid leukemia bridging to allogeneic hematopoietic stem cell transplantation after remission"],"prefix":"10.3389","volume":"15","author":[{"given":"Xiaojuan","family":"Miao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanrong","family":"Shuai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yilan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangcui","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangyi","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex H.","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,5,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26822","article-title":"Acute myeloid leukemia: 2023 update on diagnosis, risk-stratification, and management","volume":"98","author":"Shimony","year":"2023","journal-title":"Am J Hematol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-023-05406-z","article-title":"Salvage hematopoietic stem cell transplantation for patients with higher leukemia burden in relapsed or refractory acute myeloid leukemia: A ten-year study","volume":"102","author":"Jiang","year":"2023","journal-title":"Ann Hematol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.14140","article-title":"Azacitidine-venetoclax versus azacitidine salvage treatment for primary induction failure or first relapsed acute myeloid leukaemia patients","volume":"112","author":"Petit","year":"2024","journal-title":"Eur J Haematol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1182\/hematology.2020000134","article-title":"Car T Cells for other pediatric non-B-cell hematologic Malignancies","volume":"2020","author":"Lamble","year":"2020","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02754-1","article-title":"Impact of tumor microenvironment on efficacy of anti-CD19 Car T cell therapy or chemotherapy and transplant in large B cell lymphoma","volume":"30","author":"Locke","year":"2024","journal-title":"Nat Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00227","article-title":"C-type lectin-like receptors as emerging orchestrators of sterile inflammation represent potential therapeutic targets","volume":"9","author":"Chiffoleau","year":"2018","journal-title":"Front Immunol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-04-1659","article-title":"C-type lectin-like Molecule-1: A novel myeloid cell surface marker associated with acute myeloid leukemia","volume":"64","author":"Bakker","year":"2004","journal-title":"Cancer Res"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-017-0553-5","article-title":"Car-T cells targeting Cll-1 as an approach to treat acute myeloid leukemia","volume":"11","author":"Wang","year":"2018","journal-title":"J Hematol Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.b.21540","article-title":"The Clec12a receptor marks human basophils: potential implications for minimal residual disease detection in acute myeloid leukemia","volume":"94","author":"Toft-Petersen","year":"2018","journal-title":"Cytometry B Clin Cytom"},{"key":"B10","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s12943-016-0571-x","article-title":"Targeting acute myeloid leukemia stem cell signaling by natural products","volume":"16","author":"Siveen","year":"2017","journal-title":"Mol Cancer"},{"key":"B11","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/cas.12817","article-title":"Therapeutic strategies targeting cancer stem cells","volume":"107","author":"Yoshida","year":"2016","journal-title":"Cancer Sci"},{"key":"B12","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s13045-019-0726-5","article-title":"Targeting Cll-1 for acute myeloid leukemia therapy","volume":"12","author":"Ma","year":"2019","journal-title":"J Hematol Oncol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"e006857","DOI":"10.1136\/jitc-2023-006857","article-title":"Valproic acid increases Car T cell cytotoxicity against acute myeloid leukemia","volume":"11","author":"Wen","year":"2023","journal-title":"J Immunother Cancer"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01703-0","article-title":"Characteristics of anti-Cll1 based car-T therapy for children with relapsed or refractory acute myeloid leukemia: the multi-center efficacy and safety interim analysis","volume":"36","author":"Zhang","year":"2022","journal-title":"Leukemia"},{"key":"B15","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s13045-022-01308-1","article-title":"First-in-human Phase I study of Cll-1 car-T cells in adults with relapsed\/refractory acute myeloid leukemia","volume":"15","author":"Jin","year":"2022","journal-title":"J Hematol Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.931452","article-title":"Donor-derived CD7 car-T therapy followed by allogeneic hematopoietic stem cell transplantation for acute T-lymphocytic leukemia associated with hepatitis B: A case report","volume":"13","author":"Li","year":"2022","journal-title":"Front Immunol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1200\/jco.21.00389","article-title":"Donor-derived CD7 chimeric antigen receptor T Cells for T-Cell acute lymphoblastic leukemia: first-in-human, phase I trial","volume":"39","author":"Pan","year":"2021","journal-title":"J Clin Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17746","article-title":"Updates on targeted therapies for acute myeloid leukaemia","volume":"196","author":"Kayser","year":"2022","journal-title":"Br J Haematol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2022.103607","article-title":"Diagnosis and treatment of therapy-related acute myeloid leukemia","volume":"171","author":"Strickland","year":"2022","journal-title":"Crit Rev Oncol Hematol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.2174\/2589977515666230220092125","article-title":"Chimeric antigen receptor T-cell therapy in cancer: A critical review","volume":"15","author":"Sharma","year":"2023","journal-title":"Curr Drug Res Rev"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.1043","article-title":"Cd44v6 chimeric antigen receptor T cell specificity towards aml with Flt3 or Dnmt3a mutations","volume":"12","author":"Tang","year":"2022","journal-title":"Clin Transl Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1145441","article-title":"Demethylating therapy increases cytotoxicity of Cd44v6 car-T cells against acute myeloid leukemia","volume":"14","author":"Tang","year":"2023","journal-title":"Front Immunol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1080\/2162402x.2023.2248826","article-title":"Car-T cells dual-target CD123 and Nkg2dls to eradicate aml Cells and selectively target immunosuppressive Cells","volume":"12","author":"Jin","year":"2023","journal-title":"Oncoimmunology"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1016\/j.cell.2018.05.013","article-title":"Genetic inactivation of CD33 in hematopoietic stem cells to enable Car T cell immunotherapy for acute myeloid leukemia","volume":"173","author":"Kim","year":"2018","journal-title":"Cell"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01253-x","article-title":"T-cell-based immunotherapy of acute myeloid leukemia: current concepts and future developments","volume":"35","author":"Daver","year":"2021","journal-title":"Leukemia"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2017.05.024","article-title":"Treatment of acute myeloid leukemia with T cells expressing chimeric antigen receptors directed to C-type lectin-like Molecule 1","volume":"25","author":"Tashiro","year":"2017","journal-title":"Mol Ther"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1389227\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T04:23:53Z","timestamp":1715574233000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1389227\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,13]]},"references-count":26,"alternative-id":["10.3389\/fimmu.2024.1389227"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2024.1389227","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,13]]},"article-number":"1389227"}}